What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
In a real-life COPD and asthma population (including asthmatic patients with features of COPD), the proportion of patients satisfying selection criteria applied in randomised controlled trials assessing the efficacy of biologics remains limited to less than 10% of the whole population.
Authors
- L. Grassion (ORCID: https://orcid.org/0000-0002-1909-9755)
- Camille Taillé (ORCID: https://orcid.org/0000-0001-9768-5728)
- M. Zysman (ORCID: https://orcid.org/0000-0003-1459-2409)
- Jésus Gonzalez‐Bermejo (ORCID: https://orcid.org/0000-0003-2395-4694)
- ARNAUD AB BOURDIN (ORCID: https://orcid.org/0000-0002-4645-5209)
- Arthur Pavot (ORCID: https://orcid.org/0000-0001-9602-1815)
- Nicolas‐Charles Roche
- M. Gueçamburu
- Fanchon Herman (ORCID: https://orcid.org/0009-0000-8358-5320)
- Pierre‐Olivier Girodet (ORCID: https://orcid.org/0000-0002-9298-9711)
- Patrick Berger (ORCID: https://orcid.org/0000-0003-4702-0343)
- Nicolas Molinari (ORCID: https://orcid.org/0000-0002-1786-0088)
Institutions
- Université de Bordeaux (FR)
- Inserm (FR)
- Université de Montpellier (FR)
- Sorbonne Université (FR)
- Sorbonne Paris Cité (FR)
- Hôpital Cochin (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Bordeaux Population Health (FR)
- Hôpital Cardiologique du Haut-Lévêque (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- Centre de Recherche Cardio-Thoracique de Bordeaux (FR)
Publication Details
- Journal
- BMJ Open Respiratory Research
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1136/bmjresp-2024-002702
- Citations
- 5
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- GlaxoSmithKline
- Sanofi
- Chiesi Foundation